These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 26883177)

  • 1. Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature.
    Caparello C; Vivaldi C; Fornaro L; Musettini G; Pasquini G; Catanese S; Masi G; Lencioni M; Falcone A; Vasile E
    Future Oncol; 2016 Apr; 12(7):901-8. PubMed ID: 26883177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
    Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
    Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):105-11. PubMed ID: 21382702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
    Reure J; Follana P; Gal J; Evesque L; Cavaglione G; Saint A; François E
    Oncology; 2016; 90(5):261-6. PubMed ID: 27097162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
    Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
    Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
    Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
    Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
    Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
    Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer.
    Hann A; Bohle W; Egger J; Zoller W
    Sci Rep; 2017 Jan; 7():41549. PubMed ID: 28139684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second line treatment options for pancreatic cancer.
    Passero FC; Saif MW
    Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [FOLFIRINOX Combination Chemotherapy in Patients with Metastatic or Recurrent Pancreatic Cancer--A Single Institution Experience].
    Takeda Y; Katsura Y; Ohmura Y; Morimoto Y; Ishida T; Motoyama Y; Ohneda Y; Sato Y; Kuwahara R; Murakami K; Naito A; Kagawa Y; Okishiro M; Takeno A; Egawa C; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2360-3. PubMed ID: 26805364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
    Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
    Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma.
    Sadot E; Doussot A; O'Reilly EM; Lowery MA; Goodman KA; Do RK; Tang LH; Gönen M; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2015 Oct; 22(11):3512-21. PubMed ID: 26065868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
    Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
    Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of locally advanced pancreatic cancer with FOLFIRINOX].
    Strobel O; Büchler MW
    Chirurg; 2016 Aug; 87(8):699. PubMed ID: 27418266
    [No Abstract]   [Full Text] [Related]  

  • 20. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.